Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Juanjuan Zhao, Quan Yuan, Haiyan Wang, Wei Liu, Xuejiao Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jinxiu Li, Shen Qian, Congming Hong, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Qing He, Zhiyong Li, Bin He, Tianying Zhang, Shengxiang Ge, Lei Liu, Jun Zhang, Ningshao Xia, Zheng Zhang
doi: https://doi.org/10.1101/2020.03.02.20030189
Juanjuan Zhao
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quan Yuan
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiyan Wang
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Liu
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuejiao Liao
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingying Su
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Wang
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Yuan
3Department for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tingdong Li
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinxiu Li
4Department of Critical Care Medicine,Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shen Qian
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Congming Hong
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fuxiang Wang
3Department for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingxia Liu
3Department for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaoqin Wang
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing He
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyong Li
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin He
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianying Zhang
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shengxiang Ge
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhangzheng1975@aliyun.com liulei3322@aliyun.com sxge@xmu.edu.cn zhangj@xmu.edu.cn
Lei Liu
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhangzheng1975@aliyun.com liulei3322@aliyun.com sxge@xmu.edu.cn zhangj@xmu.edu.cn
Jun Zhang
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhangzheng1975@aliyun.com liulei3322@aliyun.com sxge@xmu.edu.cn zhangj@xmu.edu.cn
Ningshao Xia
2The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Zhang
1Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
5The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhangzheng1975@aliyun.com liulei3322@aliyun.com sxge@xmu.edu.cn zhangj@xmu.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.

Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed.

Results Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006).

Conclusions The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Not a study of clinical trial

Funding Statement

This study was supported by Bill & Melinda Gates Foundation.The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

We will share individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices). Also redacted Study Protocol and Statistical Analysis Plan will be shared. The data will be available beginning 6 months after the major findings from the final analysis of the study were published, ending 2 years later. The data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis. Proposals should be directed to zhangzheng1975@aliyun.com or zhangj@xmu.edu.cn. To gain access, data requestors will need to sign a data access agreement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 03, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
Juanjuan Zhao, Quan Yuan, Haiyan Wang, Wei Liu, Xuejiao Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jinxiu Li, Shen Qian, Congming Hong, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Qing He, Zhiyong Li, Bin He, Tianying Zhang, Shengxiang Ge, Lei Liu, Jun Zhang, Ningshao Xia, Zheng Zhang
medRxiv 2020.03.02.20030189; doi: https://doi.org/10.1101/2020.03.02.20030189
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
Juanjuan Zhao, Quan Yuan, Haiyan Wang, Wei Liu, Xuejiao Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jinxiu Li, Shen Qian, Congming Hong, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Qing He, Zhiyong Li, Bin He, Tianying Zhang, Shengxiang Ge, Lei Liu, Jun Zhang, Ningshao Xia, Zheng Zhang
medRxiv 2020.03.02.20030189; doi: https://doi.org/10.1101/2020.03.02.20030189

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9772)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1561)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11649)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4661)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)